VXRT

Bull points

• Results from recent preclinical studies show that our new avian flu influenza vaccine was 100% protective against death in a robust ferret clade 2.3.4.4b challenge model compared with 0% survival in placebo treated animals.
• We believe that our avian influenza program has the potential as a partnership and business development opportunity and look forward to sharing more data from the program later this year.
• We believe the relatively short timeline for advancing this new avian flu vaccine candidate to preclinical studies reinforces the power of our vast platform to enable rapid development of novel vaccines that can address the dynamic and evolving infectious disease landscape.

Bear points

• As announced in the press release today, I had delivered my notice to resign from Vaxar as Chief Financial Officer.
• the stop work order did impact the 10,000-person cohort of this study, but we continued with the 400-person Sentinel study.
• we had to make some difficult choices in order to achieve our upcoming milestones within our existing cash position. That includes rationalizing our costs through another round of workforce reductions in the past few weeks.